4-Star Stocks Poised to Pop: Novo Nordisk
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Danish drug giant Novo Nordisk (NYS: NVO) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Novo Nordisk's business and see what CAPS investors are saying about the stock right now.
Novo Nordisk facts
|Headquarters (founded)||Bagsvaerd, Denmark (1925)|
|Market Cap||$80.6 billion|
|Trailing-12-Month Revenue||$11.7 billion|
|Management||CEO Lars Sorensen (since 2000)|
CFO Jesper Brandgaard (since 2000)
|Return on Equity (average, past 3 years)||39.0%|
|Cash/Debt||$3.2 billion / $150.9 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 559 members who have rated Novo Nordisk believe the stock will outperform the S&P 500 going forward.
Although the chess game between Novo and whoever finally snaps up [Amylin] will accelerate this year, it may be ultimately pointless. ... What will give [Novo Nordisk] the leg up, perhaps the killing trump, is their rumored work on an insulin tablet. If Diabetes can ultimately be controlled by a pill rather than an injection, no matter how infrequent the stab, the successful developer of that pill will own the field. And, even now, [Novo Nordisk] leads the pack in nearly all aspects of diabetes care. ... Good long term bet, but I'm playing for the short term victory here.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Novo Nordisk may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.